![]() |
Name |
(R,3E,5E)-1-(3,5-dihydroxy-2,4-dimethylphenyl)-1-methoxyhepta-3,5-dien-2-one
|
Molecular Formula | C16H20O4 | |
IUPAC Name* |
1-(3,5-dihydroxy-2,4-dimethylphenyl)-1-methoxyhepta-3,5-dien-2-one
|
|
SMILES |
CC=CC=CC(=O)C(OC)c1cc(O)c(C)c(O)c1C
|
|
InChI |
InChI=1S/C16H20O4/c1-5-6-7-8-13(17)16(20-4)12-9-14(18)11(3)15(19)10(12)2/h5-9,16,18-19H,1-4H3/b6-5+,8-7+/t16-/m1/s1
|
|
InChIKey |
ACLGASWHSGTLJE-KBHRAGRXSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 276.33 | ALogp: | 3.1 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 20 | QED Weighted: | 0.632 |
Caco-2 Permeability: | -4.726 | MDCK Permeability: | 0.00001970 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.137 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.01 |
Blood-Brain-Barrier Penetration (BBB): | 0.152 | Plasma Protein Binding (PPB): | 96.16% |
Volume Distribution (VD): | 0.485 | Fu: | 2.96% |
CYP1A2-inhibitor: | 0.11 | CYP1A2-substrate: | 0.545 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.712 |
CYP2C9-inhibitor: | 0.039 | CYP2C9-substrate: | 0.701 |
CYP2D6-inhibitor: | 0.038 | CYP2D6-substrate: | 0.64 |
CYP3A4-inhibitor: | 0.041 | CYP3A4-substrate: | 0.469 |
Clearance (CL): | 4.994 | Half-life (T1/2): | 0.659 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.339 |
Drug-inuced Liver Injury (DILI): | 0.08 | AMES Toxicity: | 0.226 |
Rat Oral Acute Toxicity: | 0.668 | Maximum Recommended Daily Dose: | 0.948 |
Skin Sensitization: | 0.955 | Carcinogencity: | 0.106 |
Eye Corrosion: | 0.012 | Eye Irritation: | 0.907 |
Respiratory Toxicity: | 0.949 |